GSK Announces Positive Phase III Data for Next-Generation Low Carbon Ventolin Inhaler

GSK plc has reported positive phase III data for its next-generation low carbon version of Ventolin (salbutamol) metered dose inhaler (MDI). The data confirm therapeutic equivalence and a comparable safety profile to the current version, which uses HFA-134a propellant. The new formulation, containing HFA-152a propellant, has the potential to reduce greenhouse gas emissions by 92% per inhaler. GSK plans to proceed with regulatory submissions, with a launch expected from 2026. This development is significant as approximately 300 million salbutamol MDIs are sold globally each year, and GSK's current salbutamol MDI accounts for nearly half of the company's total global carbon footprint. The new inhaler aims to provide a more sustainable option for patients with respiratory diseases like asthma and COPD, which affect nearly half a billion people worldwide.